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Abstract: High-throughput cellular profiling has successfully stimulated early drug discovery pipelines by facilitating 
targeted as well as opportunistic lead finding, hit annotation and SAR analysis. While automation-friendly universal assay 
formats exist to address most established drug target classes like GPCRs, NHRs, ion channels or Tyr-kinases, no such cel-
lular assay technology is currently enabling an equally broad and rapid interrogation of the Ser/Thr-kinase space. Here we 
present the foundation of an emerging cellular Ser/Thr-kinase platform that involves a) coexpression of targeted kinases 
with promiscuous peptide substrates and b) quantification of intracellular substrate phosphorylation by homogeneous TR-
FRET. Proof-of-concept data is provided for cellular AKT, B-RAF and CamK2 assays. Importantly, comparable activity 
profiles were found for well characterized B-Raf inhibitors in TR-FRET assays relying on either promiscuous peptide 
substrates or a MEK1(WT) protein substrate respectively. Moreover, IC50-values correlated strongly between cellular TR-
FRET assays and a gold standard Ba/F3 proliferation assay for B-Raf activity. Finally, we expanded our initial assay 
panel by screening a kinase-focused cDNA library and identified starting points for >20 cellular Ser/Thr-kinase assays.  
INTRODUCTION 
  Over the last decades, cellular screening and profiling 
efforts have positively impacted early drug discovery pipe-
lines from initial hit finding through lead optimization [1, 2]. 
The development of broadly applicable assay technologies, 
e.g. Ca
2+-influx assays, cAMP quantitation and other secon-
dary messenger assays for GPCRs or ion channels [3, 4], 
reporter gene assays for NHRs [5, 6] or Ba/F3 proliferation 
assays for tyrosine kinases [7, 8] have facilitated the system-
atic exploitation of traditional drug target families. New plat-
form technologies continue to be developed to better suit the 
needs and economics of (u)HTS, to help tackle “difficult” 
and orphan targets or simply to provide orthogonal readout 
alternatives for hit reconfirmation purposes [9-12].  
  Recent advances in automated uHTS technologies have 
enabled the quantitative and parallel interrogation of arrays 
of cellular assays [8, 14]. In an earlier study, we reported on 
an automated large-scale experiment profiling 35 cellular 
Tyr-kinase assays against a focused inhibitor library [8]. 
Several repurposing opportunities for known drugs and pos-
sible opportunistic entry points for future drug discovery 
programs were identified. A similarly rich set of automation 
friendly assays is not currently available to interrogate the 
Ser/Thr-kinase space in an equally effective manner. Promis-
ing attempts have been made to quantify intracellular protein 
phosphorylation of selected Ser/Thr-kinase substrates in a 
HTS compatible format [9, 15, 16]. However, the generaliza-
tion of these strategies is currently hindered by the limited 
availability of high-quality phospho-specific antibodies. 
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  Here, we present the foundation of a cellular Ser/Thr-
kinase assay platform that relies on promiscuous peptide 
substrates for the quantification of intracellular kinase activi-
ties.  In vitro, a minimal reagent set of three peptide sub-
strates in conjunction with one phospho-specific antibody 
[17] is sufficient for the development of >100 biochemical 
Ser/Thr-kinase assays (KinEASE
TM-platform, Cisbio Inter-
national). We have translated this biochemical platform into 
a cellular format while maintaining the original homogene-
ous addition-only protocol as well as the HTS-friendly TR-
FRET readout [18-21]. In the case of B-Raf(V600E) targeted 
TR-FRET assays we found that a set of selected reference 
compounds returned comparable activity profiles for both 
protein and peptide substrate based cellular assays. Overex-
pressed target kinases like AKT and CamK2 remained re-
sponsive to upstream activation pathways. Finally, through 
cDNA screening we were able to identify starting points for 
>20 cellular Ser/Thr-kinase assays covering diverse branches 
of the phylogenetic kinome tree. In general, cellular Ser/Thr-
kinase assays were readily adaptable to high density screen-
ing in 384-well and 1536-well microtiter plates and are 
therefore considered well suited for future automated profil-
ing campaigns.  
MATERIALS AND METHODS 
Materials 
  Europium-conjugated pSTK (61PSTKAY), pAkt (61P15 
KAYC) pMEK1/2 (61P17KAYC), cMyc (61MYCKLB) 
antibodies and XL665-conjugated FLAG (61FG2XLB) and 
His6 (61HISXLB) antibodies were purchased from Cisbio, 
US. Unconjugated B-Raf antibody was from Santa Cruz Bio-
technology (sc-5284), pMEK1/2 antibody from Cell Signal-
ing Technology (9121), anti-FLAG M2 from Sigma. TR-
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well or 1536-well plates (Greiner Bio One). pcDNA5TO 
plasmid, HEK293 T-Rex cells, hygromycin, zeocin, and 
blasticidin were purchased from Invitrogen. Plasmid 
pSEMS1-26m was obtained from Covalys. Wortmannin and 
LY294002 were from Calbiochem and staurosporine from 
Sigma. Other reference compounds were synthesized at 
GNF. 
Generation of Substrate Constructs 
 Peptide  substrate  sequences were epitope-tagged and 
fused to AGT, i.e. the SNAP-tag [22-24]. Generic peptide 
substrates sequences were previously described [17]. For 
simplicity, SNAP-peptide constructs will be referred to as 
cSTKpep-1, 2 and 3. Complementary DNA oligonucleotides 
were synthesized (Valuegene) comprising the three peptide 
substrates with flanking Myc and FLAG epitope tags at the 
amino- and carboxy-terminus, respectively. Oligonucleotides 
were annealed and the resulting dsDNA ligated the into 
BamHI and NotI sites of pSEMS1-26m (Covalys). Full-
length protein substrates like MEK1 were similarly epitope-
tagged:  A two-step PCR protocol using sense primer 
5'TCAGAAGAGGATCTGATGCCCAAGAAGAAGCCGA
CG3' and antisense primer 5'GTCCTTGTAGTCGACGCCA 
GCAGCATGGGTTGG3', followed by a second PCR reac-
tion using sense primer 5'GAACAACTCATCTCAGAAGA 
GGATCTGATG3', and antisense primer 5'TTACTTGTCAT 
CGTCGTCCTTGTAGTCGAC3' to add myc (amino-
terminus) and FLAG (carboxy-terminus) epitope-tags to full-
length MEK1 cDNA (MGC clone ID: BC054754). The re-
sulting second PCR product was cloned into pcDNA4 His-
Max (Invitrogen). The kinase-inactive (K97M) and domi-
nant-negative (S218/222A) constructs were generated by 
site-directed mutagenesis (QuikChange, Strategene) using 
the wild-type full-length MEK1 construct as template. 
Generation of Tetracycline Inducible Kinase Constructs, 
Single and Double Stable Cell Lines 
  Full-length B-Raf wild-type (WT) and B-Raf(V600E) 
(NM_004333) cDNAs were subcloned from pcDNA3.1 into 
pcDNA5TO (Invitrogen) using HindIII/ Not1 restriction en-
zyme sites. The kinase-inactive (KD) double mutant B-Raf 
(V600E, K483M) was generated by site-directed mutagene-
sis. Akt1 (NM_005163) cDNA was subcloned from 
pcDNA3.1 into pcDNA5TO (Invitrogen) using BamHI/XbaI 
restriction enzyme sites and a C-terminal His-tag was added 
to the amino-terminus by PCR. The kinase-inactive AKT-
KD (K179M) point mutant was generated by site-directed 
mutagenesis.  HEK293 T-Rex cells (Invitrogen) were cul-
tured in DMEM supplemented with 10% fetal bovine serum 
(Hyclone) and 5μg/ml blasticidin. Stable pools of cells con-
stitutively expressing either cSTKpeptide or MEK1 protein 
substrates were generated by transfection of cDNA plasmids 
and selection in G418 (1 mg/ml) or zeocin (200 μg/ml), re-
spectively. Double stable cell lines expressing tetracycline-
inducible kinases were subsequently generated by transfec-
tion of these “substrate-only” HEK293 T-Rex cells and se-
lection in medium containing 175μg/ml hygromycin B.  
Cellular Ser/Thr-Kinase Assays by Transient Reverse 
Transfection (384-Well Plates) 
  HEK293 cells were transfected using Fugene 6 (Roche) 
at a density of 8000 cells/well in 384-well plates and a final 
transfection volume of 30μl. The amounts of kinase and sub-
strate plasmids per well varied for each experiment and are 
specified in the figure legends. Cell lysis and detection of 
phosphorylated or total substrate levels was performed 48h 
post transfection by addition of 30μl detection buffer (50 
mM Hepes pH 7.2, 0.1% BSA, 20mM EDTA, 0.8M KF, and 
2% Triton) containing anti-FLAG XL665 (2ng/ul) and Eu-
pSTK (0.18ng/μl) or Eu-pMEK1 (0.24ng/μl). For the relative 
determination of total substrate levels 30μl detection buffer 
was added per well containing anti-FLAG XL665 (2ng/μl) 
and Eu-cMyc (0.3ng/μl). Plates were incubated for 3-6h at 
room temperature and TR-FRET readings taken on Acquest, 
Analyst GT (Molecular Devices Corp.), Envision or Viewlux 
(Perkin Elmer) plate readers. Emission readings at 671nm 
and 618nm were expressed as a ratio and multiplied by a 
constant value of 100 to obtain “TR-FRET Ratios”.  
cDNA Screening 
  cDNA libraries and screening protocols were applied 
essentially as previously described [25, 26]. Briefly, a kinase 
focused library was assembled consisting of approximately 
800 cDNAs encoding human or mouse derived ser-
ine/threonine and tyrosine kinases. Plasmids were arrayed 
into 384-well plates at 25ng per well. The transfection mix-
ture was prepared by combining plasmid DNA for cSTKpep- 
1, 2 or 3 constructs and Fugene-6, in serum-free DMEM 
(Invitrogen). After a 20min incubation at room temperature, 
5μl of the transfection mixture was dispensed such that each 
well contained 3.125ng of the respective cSTKpep plasmid. 
Subsequently, 25μl cells were added to each well 
(8000/well) using μFill (Bio-Tek) dispensers. Cell lysis and 
plate reads were conducted 48h post transfection as de-
scribed above. cDNA screens were performed in duplicates 
for each substrate construct. Prespotted known active kinases 
served as positive controls in each screen; “substrate-only” 
wells containing only cSTKpep plasmids served as negative 
controls. Kinase-induced substrate phosphorylation was ex-
pressed relative to substrate-only control wells and average 
fold-activation values were calculated from duplicates.  
Small Molecule Inhibition Studies 
  For LMW screening purposes in 384-well plates 
HEK293 T-Rex cells were either transiently transfected with 
tetracycline-inducible kinase and substrate constructs at a 
previously optimized ratio following the above mentioned 
reverse transfection protocol. Alternatively, double stable 
cells were plated directly at a density of 8,000cells/well in a 
volume of 30μl. 24h post plating, tetracycline (1μg/ml) was 
added to induce kinase expression for approximately 16h 
prior to compound addition. Kinase inhibitors were resus-
pended in DMSO and 12 point 1:3 serial dilutions were pre-
pared. 100nl of compound stocks were pintool transferred 
into the assay plates resulting in a final DMSO concentration 
of 0.3%. After a 2h incubation period TR-FRET detection 
reagents detection reagents were added. For 1536-well plate 
screening cells were either transiently transfected in bulk or 
stable cells were seeded directly. For transient bulk transfec-
tions the transfection reagent mixture was prepared accord-
ing to the following ratios: plasmid DNA: fugene 6: serum 
Free media = 1μg: 3μl: 21μl. For every 1ml of cells 1.25μg 
of kinase plasmid, 0.156μg of substrate plasmid (8:1), 4.22μl 
of Fugene 6 and 30μl of serum free media was prepared. The 
transfection mixture was then incubated at room temperature 56    Current Chemical Genomics, 2008, Volume 1  Adams et al. 
for 30 min and mixed into a HEK293 cell suspension (400 
cells/μl). 2,000 cells/well were dispensed in 1536-well plates 
in 5μl media volumes and incubated at 37˚C. Kinase expres-
sion was induced in stable cells after 24h incubation through 
the addition of 1μl tetracycline (5μg/ml) followed by an ad-
ditional 4-16 h incubation time before compound addition. 
Compound treatment in transient transfection experiments 
occurred 48h post seeding. In either case, 50nl DMSO stocks 
were pintool transferred into each well and incubated at 37˚C 
for a 2h period before addition of 4μl detection reagents. TR-
FRET readings were taken after another incubation time of 
4-24h. Z’ scores were determined as described [27].  
Immunoblot Analysis 
  HEK293 cells were harvested 48h post transfection in 
cell lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 
mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5mM sodium 
pyrophosphate, 1 mM Beta-glycerophosphate, 1 mM Na3 
VO4, 1ug/ml leupeptin, supplemented with 1X protease in-
hibitors (Sigma). Cellular extracts were resolved by SDS-
PAGE (10% Bis-Tris Gel, Invitrogen), transferred to nitro-
cellulose membranes, and immunoblotted with the indicated 
antibodies. Immunolabeled proteins were visualized through 
Odyssey infrared imaging (Li-Cor, Lincoln, NE), with IR-
Dye
TM800 (Rockland Immunochemicals) and AlexaFluor® 
680 (Molecular Probes)-conjugated fluorescent secondary 
antibodies. 
B-Raf(V600E)-Ba/F3 Proliferation Assay 
  The B-Raf(V600E)-Ba/F3 cell line was generously pro-
vided by Markus Warmuth (GNF). Ba/F3 cells were counted 
and diluted to a final concentration of 75,000 cells/ml in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic of biochemical and cellular TR-FRET Ser/Thr-kinase assays. (A) Biochemical KinEASE assay. (B) and (C) Cellular 
Ser/Thr-kinase assays. Target kinases are overexpressed in combination with cSTK peptide substrates (B) or full-length protein substrates 
like MEK1 (C). TR-FRET between phospho-specific and epitope-tag targeted antibodies is used to quantify intracellular substrate phos-
phorylation post lysis.  
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RPMI media and 50μl/well were plated into 384-well white 
solid bottom plates. 50nl of a 10mM compound stock in 
DMSO were pintool transferred followed by a 48h incuba-
tion time at 37°C for 48h. Finally, 25μl Cell-Titer-Glo 
(Promega) detection reagent was added each and lumines-
cence read were taken on a CLIPR (Molecular Devices 
Corp.) reader. 
RESULTS AND DISCUSSION  
Translating Biochemical STK-Assays into Cells 
  Cisbio’s KinEASE platform utilizes a minimal reagent 
set of three promiscuous peptide substrates (STK-peptides) 
sharing a common Ser-phosphorylation site and one corre-
sponding phospho-specific antibody (pSTK) to support a 
panel of >100 biochemical Ser/Thr-kinase assays (Fig. 1A, 
[17]).  In vitro, the incubation of purified kinases with bi-
otinylated peptide substrates leads to substrate phosphoryla-
tion quantifiable by TR-FRET [28]. We sought to translate 
this biochemical assay into a cellular format by first coex-
pressing Ser/Thr-kinases with reengineered cellular STK-
peptide substrates –subsequently referred to as cSTK-pep– 
and then quantifying intracellular peptide phosphorylation 
using a simple homogeneous addition-only protocol.  
  To this end, we flanked the STK peptide sequences with 
N-terminal Myc- and C-terminal Flag-epitopes. The result-
ing oligopeptides were fused to hAGT carrier proteins 
(“SNAP-tag”) [22-24] to support their stable cellular expres-
sion and to have an option for a future direct functionaliza-
tion of intracellular cSTKpep-1, 2 and 3 substrates (Fig. 1B). 
The added epitope tags enable the quantification of either 
total substrate expression or substrate phosphorylation. To 
have a reference for peptide based cellular Ser/Thr-kinase 
assays we developed MEK1 as a model full-length protein 
substrate of kinases such as B-Raf or B-Raf(V600E), an ac-
tivated oncogenic kinase mutant and established cancer drug 
target [31, 32]. 
Case Study 1: B-Raf – Peptide vs Protein Substrates and 
Pharmacological Assay Validation 
  When the cSTKpep-3 substrate was expressed alone in 
HEK293 cells the observed basal phosphorylation levels 
derived from endogenous Ser/Thr-kinase activities were low, 
barely detectable by TR-FRET with weak phospho-specific 
bands being detectable by western blotting (Fig. 2A, C and 
E). Similar observations were made with peptide substrates 
cSTKpep-1 and cSTKpep-2 (Fig. 8 and data not shown). 
  Cotransfection of cSTKpep-3 with B-Raf(V600E) re-
sulted in a several fold increase in substrate phosphorylation 
by both western blotting and TR-FRET (Figs. 2A, C and E). 
Moreover, B-Raf(V600E)-induced cSTKpep-3 phosphoryla-
tion was both dependent on the kinase activity as well as the 
presence of the target phosphorylation site since no 
cSTKpep-3 phosphorylation was detected when using a 
kinase-inactive mutant version of B-Raf(V600E), B- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Case Study 1: B-Raf – Comparison of intracellular cSTKpep-3 vs. Mek1 protein substrates.  
HEK293 cells were transiently double transfected (1g kinase DNA and/or 1g substrate DNA in 6-well dish) as indicated and immunoblot-
ted. B-Raf constructs were combined with either (A) cSTKpep-3 or (B) kinase-inactive, MEK1(KD) protein substrates; (C)-(E) 384-well 
TR-FRET assays using a transient reverse transfection protocol. (E) B-Raf(WT) and B-Raf(V600E) constructs were cotransfected at 50ng or 
25ng with a 2-fold serial dilution of cSTKpep-3 ranging from 25ng (black bar) to 1.5ng (white bar).  
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Raf(V600E)-KD or a Ser/Ala-mutant of cSTKpep-3 (cSTK 
pep-3-SA) (Fig. 2A and C). 
  As expected, cSTKpep-3 phosphorylation could be 
modulated by both the amounts of substrate and kinase 
plasmids transfected as well as by the activation state of the 
transfected kinase (Fig. 2E). Comparable results were ob-
tained when using kinase-inactive, MEK1(KD), as a sub-
strate (Figs. 2B and D ); cotransfection of MEK1 with B-
Raf(V600E) resulted in increased MEK1 phosphorylation as 
detected by both western blotting and TR-FRET.  
  These results demonstrate that promiscuous Ser/Thr-
kinase peptide substrates can be expressed in cells with low 
detectable levels of background phosphorylation and that 
significant increases in peptide substrate phosphorylation can 
be achieved through the overexpression of a target Ser/Thr-
kinase. Since both the degree of background phosphorylation 
as well as kinase activities depend on the amounts of expres-
sion constructs applied in the transient transfection reactions, 
careful titrations of both constructs need to be performed to 
obtain optimal assay windows.  
  For the pharmacological evaluation we generated double 
stable cells constitutively expressing either cSTKpep-3, 
wild-type MEK1(WT) or kinase-inactive MEK1(KD) sub-
strates in combination with Tet-inducible B-Raf(V600E). 
Kinase inhibitors were then tested in 384-well or 1536-well 
formats. In all cases short compound treatment times of 
around 2h were employed to minimize cytotoxicity related 
compound interference (Figs. 3 and 4, Table 1).  
  Overall, cellular TR-FRET assays performed very robus-
tly with B-Raf inhibitor A in both 384-well and 1536-well 
plates for MEK(WT), MEK(KD) or c-STKpep-3 substrates 
with Z’=0.6-0.9. Moreover, the observed potencies of a 
panel of selective in-house B-Raf inhibitors correlated very 
well in cSTKpep-3 and MEK1(WT) TR-FRET-assays 
(R
2=0.86, Table 2, Fig. 4A). Good agreement was also ob-
served when comparing TR-FRET assay results with histori-
cal Ba/F3-proliferation data for B-Raf(V600E) (R
2
cSTKpep-
3/BaF3=0.81, R
2
MEK1/BaF3= 0.94, Table 1, Fig. 4B and 4C). 
None of these B-Raf inhibitors affected basal cSTKpep-3 
and MEK1(WT) background phosphorylation in the absence 
of prior B-Raf(V600E) induction (data not shown). Finally, a 
selection of unrelated kinase inhibitors, including Wortman-
nin and LY29002 did not show any activity in either the 
cSTKpep-3 or MEK1(WT) TR-FRET assays (Table 1).  
  While B-Raf selective compounds compared very well in 
the above assays (Table 1), pronounced discrepancies were 
reproducibly observed for the activities of the highly selec-
tive MEK1/2 inhibitor PD0325901 [34, 35] and stauros-
porine, a non-selective kinase inhibitor with only weak activ-
ity against Raf-kinases in vitro. Both compounds had compa-
rable activities when using cSTKpep-3 or MEK1(WT) as B-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Pharmacological validation of Raf(V600E)/cSTKpep-3 and Raf(V600E)/MEK(WT) TR-FRET assays. IC50 curves were de-
termined for B-Raf inhibitor A in 384-well and 1536-well plates using double stable cell lines. Open circles: DMSO, solid squares: B-Raf 
inhibitor A. 
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Raf(V600E) substrates, but were inactive when using 
MEK1(KD). Similar observations of substrate dependent 
inhibitor profiles in cellular MEK-phosphorylation assays 
were recently made using an ELISA readout [36]. The un-
derlying reasons for these differences are still being investi-
gated. One possible explanation is the existence of a positive 
feedback loop driving ERK1/2 mediated (hyper)activation of 
B-Raf(V600E), although the detailed mechanism is still un-
clear and factors including the cellular context and predomi-
nant Raf isoforms involved may have an impact [29, 30]. 
According to this model, PD0325901 and staurosporine indi-
rectly affect B-Raf(V600E) activity on cSTKpep-3 and 
MEK1(WT) by targeting downstream kinases and thereby 
antagonizing the activating feedback loop. Overexpression 
of MEK1(KD) on the other hand would exert the same effect 
as small molecule MEK1/2 inhibition, thereby rendering the 
residual B-Raf(V600E) activity insensitive to further 
PD0325901 inhibition. Regardless of the underlying mecha-
nistic reasons for the observed discrepancies between B-Raf 
targeted TR-FRET assays, it is interesting to note the distinc-
tions between the MEK1(WT) and MEK1(KD) assays. The 
nature and activation state of functional protein substrates 
can impact the cellular activities of upstream drug targets 
and the activity profiles of putative inhibitors. This is a po-
tentially complicating factor that needs to be investigated 
when designing cellular enzyme assays around bioactive 
substrates [15, 16]. Biologically inactive peptide substrates 
on the other hand would be expected to have a comparatively 
minor effect on intracellular signaling pathways.  
Case Study 2: Interrogating the AKT Pathway and Prob-
ing for Compound Interference 
  For a second case study we turned to AKT and its   
upstream activation pathway. AKT-dependent intracellular 
cSTKpep-3 phosphorylation could be detected by western 
blotting and by TR-FRET (Fig. 5A and 5B). In the absence 
of other efficacious AKT inhibitors staurosporine was used 
as a tool compound and found to effectively inhibit AKT-
dependent cSTKpep-3 phosphorylation (Fig. 6B). Its cellular 
potency (IC50 ~100nM) agreed with the in vitro activity 
against AKT (IC50~100nM). Comparable IC50 values were 
found for incubation periods ranging from 30min 
(IC50~240nM) to 2h (IC50~100nM) (data not shown). 
  To determine if staurosporine-induced cytotoxicity and 
the subsequent loss of kinase substrate expression affected 
the outcome of the cellular assays, we aimed to separate the 
effect of staurosporine on cSTKpep-3 phosphorylation from 
its effect on total cSTKpep-3 expression (Fig. 6A). After 
short 2h treatment staurosporine exclusively affected 
cSTKpep-3 phosphorylation, but not cSTKpep-3 expression 
levels. After an extended 48h treatment stauros-porine af-
fected phospho- as well as total-cSTKpep-3 levels with equal 
apparent potency, suggesting that the occurrence of cytotox-
icity inappropriately interfered with the assay readout.  
  These observations underline the importance of short 
compound treatment times to avoid high rates of uninterest-
ing hits in an HTS context and further highlight the benefit 
Table 1.  IC50 Profiles of B-Raf(V600E) TR-FRET and Ba/F3 Assays. Standard deviations for data are listed in parentheses (n=4-6). 
IC50 [nM] 
MEK(WT) MEK(KD) cSTKpep-3 Ba/F3  Inhibitor 
384-well 384-well 384-well  384-well 
Cmpd A  2(1)  1(1)  4(2)  4(3) 
Cmpd B  112(31)  4(1)  140(77)  84(7) 
Cmpd C  89(31)  21(8)  51(36)  41(3) 
Cmpd D  4(2)  2(1)  4(3)   
Cmpd E  70(27)  19(1)  15(16)  33(22) 
Cmpd F  1153(140)  7473(1615)  833(63)   
Cmpd G  846(601)  41(12)  100(2)  1160(394) 
Cmpd H  10(5)    2(2)   
PD0325901 88(43)  NI  122(82)  78(35) 
Bayer 43-9006  4542(1050)  376(179)  2309(625)  5000(800) 
Wortmannin NI  NI  NI   
LY294002 NI  NI  NI   
Cot inhibitor*  NI  NI  NI   
Staurosporine 117(56)  NI  106(40)   
* Cot Inhibitor: cmpd 30 [33]  60    Current Chemical Genomics, 2008, Volume 1  Adams et al. 
of the presented cellular assay format over cell proliferation 
or reporter gene assays that typically require compound in-
cubation times from several hours to days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). IC50 values of B-Raf inhibitors are strongly correlated 
between 384-well B-Raf(V600E) cSTKpep-3 and MEK1(WT) TR-
FRET and Ba/F3 proliferation assays (Table 2).  
(A) TR-FRET Raf(V600E)/cSTKpep-3 vs Raf(V600E)/MEK(WT). 
(B) TR-FRET Raf(V600E)/cSTKpep-3 vs B-Raf(V600E)-Ba/F3. 
(C) TR-FRET Raf(V600E)/MEK(WT) vs B-Raf(V600E)-Ba/F3. 
 
  Next, we aimed to interrogate the AKT pathway in 
greater detail by separating AKT activation as indicated by 
Ser473 phosphorylation, from signaling events depending on 
activated AKT such as cSTKpep-3 phosphorylation (Fig. 
7A). To this end we developed another TR-FRET assay us-
ing His-tagged AKT to monitor Ser473 phosphorylation.  
  As predicted for inhibitors of AKT activation, the PI3K 
inhibitors LY294002 and Wortmannin displayed comparable 
potencies in both AKT phosporylation (Fig. 7B) and 
cSTKpep-3 phosphorylation (Fig. 7C) assays. Moreover, the 
observed potencies of Wortmannin and LY294002 in the low 
nanomolar and low micromolar concentration ranges respec-
tively were in line with their reported in vitro and cellular 
activities on PI3K [37, 38]. Staurosporine activity on the 
other hand differed by a factor of ~100fold when quantifying 
p-AKT (IC50~6μM) versus p-cSTKpep-3 (IC50~60nM). 
These cellular activities mirror the in vitro potency of 
staurosporine on PI3K (IC50~9μM) and AKT (IC50~100nM). 
 
 
 
 
 
Fig. (5). Case Study 2: AKT dependent cSTKpep-3 phosphory-
lation.  
(A) HEK293 cells were transiently double transfected (1g kinase 
DNA and/or 1g substrate DNA in 6-well dish) as indicated and 
immunoblotted. (B)  384-well  TR-FRET assay using a transient 
reverse transfection protocol. Wild-type Akt1(WT) or kinase-
inactive Akt1(K179M) were combined with cSTKpep-3. 
 
  Together, these experiments demonstrate that the activity 
of overexpressed wild-type Ser/Thr-kinases can be respon-
sive to upstream signaling events and that assays can be de-
signed in the proposed format to interrogate a cellular path-
way at different intersection points.  
Seeding a Cellular Ser/Thr-Kinase Assay Panel 
  Having shown proof-of-concept for two important drug 
targets AKT and B-Raf, we sought to identify additional 
Ser/Thr-kinases amenable to our cellular assay approach 
through cDNA screening. A kinase focused sublibrary of 
GNF’s genome scale cDNA collection [25, 26] comprising 
approximately 800 Ser/Thr- and Tyr-kinase clones was ar-
rayed into microtiter plates. A panel of cSTKpep-1, 2 and 3 
substrates was then screened besides a number of similarly 
designed SNAP-peptide constructs containing alternative 
substrate sequences, including Crosstide (GRPRTSSFA-
EPG), MBPtide (FFKKIVTPRTPPP), CREBtide (LRREIL 
SRRPSYRK) and the p38-activation loop (LARHTDDEM 
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Fig. (6). Quantification of total- and phospho-cSTKpep levels can reveal compound interference. The importance of short compound 
incubation. 
(A) Combinations of -FLAG with -p-STK or -Myc antibodies were used to quantify either cSTKpep-phosphorylation or total cellular 
cSTKpep-3 expression by TR-FRET. (B)  and  (C)  Transient 384-well AKT/cSTKpep-3 TR-FRET assay. Cells were treated with 
staurosporine for 2h (B) or 48h (C). Open circles: phospho-cSTKpep-3; Solid circles: total-cSTKpep-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Targeting the AKT-pathway. 
(A)  TR-FRET assays were developed for the quantification of either p-AKT(Ser473) or p-cSTKpep-3. (B)  p-AKT(Ser473)  and  (C)  p-
cSTKpep phosphorylation was quantified after treatment with Staurosporine (open triangles), Wortmannin (open squares), LY294002 (open 
circles) or DMSO (closed squares). Experiments were performed in 384-well plates after transient co-transfection of AKT-His and cSTKpep-
3 into HEK293 cells.  
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TGYVA). cDNA hits resulting in >2fold S/N ratios relative 
to substrate-alone controls were picked for further activity 
and sequence confirmation. Between all 7 screens the three 
cSTKpep substrates combined scored ~86% of all hits 
(57/66) and overall higher S/N ratios than the other peptide 
substrates tested. cSTKpep-3 returned the majority of hits 
(37/57) followed by cSTKpep-2 (12/57) and c-Kinase-1 
(8/57). Ultimately, 22 distinct Ser/Thr-kinases were identi-
fied as inducers of cSTKpep phosphorylation (Table 2). Of 
these 22 Ser/Thr-kinases, 13 were already known members 
of the biochemical KinEASE-panel, whereas 9 kinases were 
newly identified. Nine out of the 13 previously known 
kinases preferred the same STK peptide substrate in vitro 
and in cells (Table 2). No Tyr-kinases were found to stimu-
late cSTKpep phosphorylation, suggesting that no indirect 
Tyr-kinase induced activation of endogenous Ser/Thr-kinase 
pathways triggered cSTKpep phosphorylation. Overall, these 
observations are consistent with the idea that the intracellular 
kinase-cSTKpep interactions were direct.  
Future Outlook and Opportunities 
  While a number of kinases already represented on the 
biochemical KinEASE panel were picked up through DNA 
screening, others were missed. Several reasons might help 
explain these findings. Preactivation of Ser/Thr-kinases ei-
ther through physiologic stimuli or via protein engineering, 
e.g. through the deletion of autoinhibitory domains or acti-
vating mutations, may be required beyond their plain over-
expression to induce cSTKpep phosphorylation. The subcel-
lular localization of kinases or their substrates, cell cycle 
dependency, cellular backgrounds and the dynamics of sig-
naling pathways all may play a role. By rescreening our 
kinase cDNA library under modified assay conditions, e.g. in 
the presence of external stimuli, nuclear targeted substrates, 
different cell types, or alternatively through the design of an 
entirely new cDNA library of activated kinase constructs we 
aim to further expand the current panel of cellular Ser/Thr-
kinase assays in the future. In the case of CamK2 we found 
that transient activation of kinase activity and subsequent 
Table 2.  An Emerging Cellular Ser/Thr-Kinase Assay Panel. Confirmed hits obtained from cSTKpep cDNA screens. fold activation 
was calculated as TR-FRET signal with kinase and cSTKpep cotransfection divided by cSTKpep alone. 
Peptide Substrate 
Gene Name  Accession number 
Biochemical Cellular 
Fold Activation  Kinase Family 
B-Raf(V600E) NM_004333    3  9.0  TKL 
Cot NM_005204    3  8.5  STE 
PKA BC054834  2  2  8.5  AGC 
Akt1 NM_005163.1  3  3  9.9  AGC 
Akt2 NM_001626  3  3  4.0  AGC 
B-RAF(WT) NM_004333    3  5.0  TKL 
CHEK2 NM_007194.2  1  3  9.0  CMGC 
MEKK3 NM_002401.3    3  8.9  STE 
MLK3 NM_002419.2    3  5.3  TKL 
Pim-2 BC018111  3  3  7.4  CAMK 
PKD1  NM_002742.1   3  9.1 CAMK 
PKD2 BC095949  1  3  5.9  CAMK 
PRKX NM_005044.1  2  2  9.0  AGC 
Aurora-A BC001280  2  2  4.3  AGC 
BRSK2 NM_003957.1  1  3  2.2  CAMK 
CAMK2* BC032784  1  1  2.4  CAMK 
MEK1-CA NM_002755    3  3.4  STE 
MKK3 BC032478    3  3.0  STE 
MKK6 NM_002758.2    3  4.9  STE 
NEK6 NM_014397.3  3  3  2.0  CAMK 
NEK7 NM_133494.1  3  3  4.0  CAMK 
PAK4 BC048238  2  3  2.9  STE 
*ionmycin stimulation. Cellular Ser/Thr-Kinase Assays Using Generic Peptide Substrates  Current Chemical Genomics, 2008, Volume 1    63 
cSTKpep-1 phosphorylation was ionomycin inducible (Fig. 
8). We believe that assay conditions can be found to activate 
additional Ser/Thr-kinases in a similar manner.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Induction of CamK2 activity. 
Transient transfection reactions were performed in 384-well plates 
as indicated. HEK 293 were reverse transfected with 50ng CamK2 
and 50ng (black bars) or 25ng (gray bars) cSTKpep-1. CamK2 
activity was induced through 5min ionomycin treatment (1μM) and 
p-cSTKpep-1 was quantified by TR-FRET. 
 
CONCLUSIONS 
  Here we present a starting point for the construction of a 
new cellular Ser/Thr-kinase assay platform that is tailored 
towards automated high density compound profiling and 
primary uHTS. We demonstrated that generic peptide sub-
strates can form a viable basis for the determination of intra-
cellular Ser/Thr-kinase activities and that a homogeneous 
TR-FRET protocol can be formulated to detect peptide 
phosphorylation in a sensitive, quantitative and automation-
friendly manner. For B-Raf we showed that peptide- and 
protein-based cellular TR-FRET assays returned well corre-
lated activity profiles for a panel of tool compounds ranging 
from highly selective to relatively promiscuous kinase in-
hibitors. Despite the overexpression of target kinases high-
potency inhibitors could be readily identified as such. In ad-
dition, overexpressed target kinases like AKT and CamK2 
remained sensitive to upstream activating signals. Impor-
tantly, short compound incubation times on the order of 1-2 
hours were sufficient to obtain robust IC50 values. This spe-
cific feature of the presented cellular TR-FRET kinase plat-
form tremendously benefits HTS applications as it avoids 
artifactual cytotoxic hits or non-specific transcriptional in-
hibitors which tend to interfere with traditional proliferation 
or reporter gene assays of Ser/Thr-kinase activity. The built-
in option to quantify relative substrate amounts as well as 
substrate phosphorylation by TR-FRET and thereby to nor-
malize for substrate expression levels further helps to sort 
out non-specific compound interference. Finally, having 
validated cellular TR-FRET assays for two important drug 
targets, we expanded our assay concept to seed a panel of 
currently >20 cellular Ser/Thr-kinase assays through cDNA 
screening. While this initial panel will mainly target full-
length wild-type kinases which are constitutively activated 
upon overexpression in HEK293 cells, a future generation of 
assays can be envisioned to include also engineered Ser/Thr-
kinases or to involve kinase activation through physiologic 
stimuli. Wherever high-quality phospho-specific antibodies 
are available, protein kinase substrates will be incorporated 
into our panel as well. However, due to the very limited 
availability of such reagents it is expected that a rapid expan-
sion and a significant coverage of the Ser/Thr-kinome will 
be initially achieved through TR-FRET assays relying on 
more broadly applicable peptide substrates like cSTKpep-1, 
2 and -3 in conjunction with the corresponding universal p-
STK antibody [17, 21]. In conclusion, the successful transla-
tion of the biochemical KinEASE assay platform into a cel-
lular assay format will aid the exploration of biological 
Ser/Thr-kinase space through automated high-throughput 
screening and profiling.  
ABBREVIATIONS 
ACP  =  automated cellular profiling 
HEK  =  human embryonic kidney 
hAGT =  O
6-alkylguanine-DNA-alkyltransferase 
(u)HTS  =  (ultra) high-throughput screening 
KD =  kinase-inactive 
LMW  =  low molecular weight 
MEK  =  mitogen-activated protein kinase/extracellular 
signal-regulated kinase kinase 
PI-3K =  phosphatidylinositol  3-kinase 
Tet =  tetracycline 
TR-FRET  =  time-resolved fluorescence resonance energy 
transfer 
WT =  wild-type 
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